2022-03-07 - Cancer Synoptic Reporting Project Group Meeting

Continue discussion:

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?

1. Primary site
2. Lymph node

Note: SSA wonders about property in this model

Will review model.  This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy.  So, observable could be modeled as presence of process changes.

Still a discussion.  What is being measured?  (Degree of presence of tumor). Can this be reproduced...base question is tumor there or not s/p therapy...tumor gone is best...everything else is questionable for the patient

1. How to handle patterns within histologies
   1. Lung (Lepidic, acinar)
   2. DCIS
   3. Bladder (differentiation)